UK's MHRA proposes 44 new laws to regulate AI in healthcare

The UK’s primary regulator for medicines and medical devices has issued a urgent call for new laws to govern the use of artificial intelligence in healthcare. The Medicines and Healthcare Products Regulatory Agency, known as the MHRA, published a comprehensive report containing forty-four specific recommendations to update current policies. This move comes as AI tools become increasingly embedded in the National Health Service and other clinical settings. Lawrence Tallon, the chief executive of the MHRA, stated that patients will soon routinely encounter AI as a standard part of their medical care. He emphasized that this integration must happen in a way that preserves public trust and confidence in the healthcare system. The agency argues that the existing regulatory framework is outdated and ill-equipped to handle the unique challenges posed by intelligent software. Without these new rules, there is a risk that patients could be exposed to unsafe or ineffective technologies. The report highlights the need for a robust legal structure that can keep pace with rapid technological advancement. This is not just a theoretical concern but a practical necessity for the future of British healthcare. The MHRA aims to ensure that innovation does not come at the cost of patient safety or privacy.

The driving force behind these recommendations is the fundamental difference between traditional medical devices and modern AI systems. Tallon explained that current regulations were designed for static products like hip replacements, stethoscopes, or plasters. These items do not change after they are approved for use. AI models, however, are dynamic. They continue to learn, adapt, and potentially drift as new data is fed into them over time. This continuous evolution makes it difficult for regulators to assess safety and efficacy using old methods. The agency proposes several key changes to address this. These include the power to continuously monitor AI products and remove them from approval if they malfunction or become less effective. There are also plans to give patients the right to know when AI is involved in their care and to access information about the specific tools used. Furthermore, the report suggests penalties for developers whose products fail to meet required standards. An AI L plate system would also allow new models to be trialled under close supervision. These measures aim to create a safer environment for testing and deployment while protecting vulnerable patients. The goal is to balance innovation with rigorous safety checks.

Public opinion on AI in healthcare is mixed, adding another layer of complexity to the regulatory challenge. A recent study from the University of Edinburgh found that patients may be less likely to share sensitive personal information, such as a history of substance abuse, if they know an AI system is processing the conversation. This hesitation could impact the quality of care if doctors lack full context about a patient’s health. Professor Henrietta Hughes, a general practitioner who contributed to the report, noted that while many patients are comfortable with AI, others prefer to opt out. She acknowledged that AI note-takers, which are used by forty percent of UK general practitioners, can make mistakes. However, she stressed that the final responsibility for correcting these notes lies with the doctors. The widespread adoption of these tools highlights the urgent need for clear guidelines. Developers and healthcare providers must work together to ensure that AI supports rather than hinders the doctor-patient relationship. Trust is the cornerstone of effective healthcare, and any technology that erodes that trust must be carefully managed.

Regulating AI is a global challenge, and no single country has yet cracked the code. Tallon admitted that there is no perfect model to copy from elsewhere. This lack of precedent means the UK must forge its own path while learning from international efforts. The stakes are high as AI moves from administrative tasks to more complex diagnostic and treatment roles. The MHRA’s recommendations serve as a starting point for a broader conversation about the future of digital health. Policymakers, clinicians, and technology companies must engage in this dialogue to create effective rules. The ultimate goal is to harness the benefits of AI while mitigating its risks. Patients deserve assurance that the technology used in their care is safe, effective, and transparent. The coming years will be critical in shaping how AI is integrated into the NHS. As the technology evolves, so too must the laws that govern it. The MHRA’s report is a significant step toward building a regulatory framework that can adapt to the changing landscape of healthcare. It sets the stage for a new era of digital medicine in the UK. The success of these efforts will depend on collaboration, transparency, and a relentless focus on patient welfare.